Table 1.
Summarized information of animal studies using human gastric and colon cancer xenograft models.
| Cancer Type | Cancer Cell Line | Dose (mg/kg) |
Treatment Schedule | Animal Number (n/Group) |
%TGI | p Value |
|---|---|---|---|---|---|---|
| Gastric | NUGC-3 | 1 | Biweekly | 11 | 27.4 | 0.0275 |
| MKN45 | 1.25 | 10 | 30.0 | 0.0378 | ||
| SNU16 | 3.25 | 12 | 52.2 | 0.0010 | ||
| GAPF006 | 6.5 | 10 | 53.3 | 0.0051 | ||
| Colon | SW48 | 1.25 | Biweekly | 10 | 55.5 | 0.0264 |
| SW620 | 2 | 6 | 49.7 | 0.0224 | ||
| Colo205 | 3.25 | 8 | 57.2 | 0.0177 | ||
| WiDr | 6.5 | 9 | 38.8 | 0.0131 |
GAPF006, gastric patient-derived xenograft model, %TGI = tumor growth inhibition, p value: Student’s t-test.